8-K: Select Medical Holdings Acquired for $3.9 Billion
Current Report (8-K)
Select Medical Holdings Corporation announced the completion of its acquisition by a consortium led by its Executive Chairman, Robert A. Ortenzio, and Welsh, Carson, Anderson & Stowe (WCAS), valuing the company at approximately $3.9 billion.
Summary
- Select Medical Holdings Corporation has been acquired by a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson & Stowe (WCAS).
- The acquisition was completed on June 30, 2026, with the merger effective July 1, 2026.
- The purchase price of $16.50 per share values the company at approximately $3.9 billion.
- This represents a premium of approximately 18% over Select Medical's unaffected share price as of November 24, 2025, and a 25% premium over its 90-day volume-weighted average closing share price.
- Following the acquisition, Select Medical's common stock will cease trading on the New York Stock Exchange as of July 1, 2026.
- The consortium, which includes existing management, will maintain effective and operational control of the company.
- The transaction was approved by Select Medical's stockholders at a Special Meeting on June 26, 2026.
- The company also announced an amendment to its Credit Agreement, establishing a new incremental term loan of $1,000,000,000.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the significant premium paid to shareholders and the continuity of management. However, the delisting and increased debt are noted as potential concerns.
Positives
- The acquisition provides a significant premium to shareholders, with a 25% premium over the 90-day volume-weighted average share price.
- The consortium, including key management, will continue to lead the company, suggesting operational continuity.
- The company secured a $1 billion incremental term loan, indicating continued access to financing for its operations or strategic initiatives.
Negatives
- Select Medical will no longer be a publicly traded company, meaning its stock will cease trading on the NYSE.
- The company is now privately held, which may reduce transparency for public investors.
Risks
- The company's future strategic direction and operational focus under private ownership are subject to the consortium's plans.
- The $1 billion incremental term loan adds to the company's debt obligations, which could impact future financial flexibility.
Future Outlook
With the acquisition complete, Select Medical will operate as a private company under the control of the consortium. The company's future strategic direction and financial performance will be guided by its new ownership.
Management Comments
- Select Medical Holdings Corporation today announced the completion of its acquisition by an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe (WCAS).
Industry Context
StockSavvy.ai notes that the acquisition of Select Medical Holdings by a private equity firm and management consortium is a significant event in the healthcare services sector. This trend of private equity investment in healthcare companies continues, driven by the sector's perceived stability and growth potential. The delisting from the NYSE signifies a shift towards private ownership, which often allows companies to focus on long-term strategies without the short-term pressures of public markets.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | William H. Frist | Russell L. Carson | Effective Time (July 1, 2026) | In connection with the closing of the Merger. |
| Director | Daniel J. Thomas | David S. Chernow | Effective Time (July 1, 2026) | In connection with the closing of the Merger. |
| Director | Katherine R. Davisson | Robert A. Ortenzio | Effective Time (July 1, 2026) | In connection with the closing of the Merger. |
| Director | Parvinderjit S. Khanuja | Effective Time (July 1, 2026) | In connection with the closing of the Merger. | |
| Director | James S. Ely III | Effective Time (July 1, 2026) | In connection with the closing of the Merger. | |
| Director | Thomas A. Scully | Effective Time (July 1, 2026) | In connection with the closing of the Merger. | |
| Director | Marilyn B. Tavenner | Effective Time (July 1, 2026) | In connection with the closing of the Merger. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amended and Restated Certificate of Incorporation | The Certificate of Incorporation was amended and restated pursuant to the terms of the Merger Agreement. | Effective Time (July 1, 2026) | Aligns corporate charter with the new ownership structure. |
| Amended and Restated Bylaws | The Bylaws were amended and restated pursuant to the terms of the Merger Agreement. | Effective Time (July 1, 2026) | Updates corporate governance procedures to reflect the new ownership and operational structure. |
Related Party Transactions
- The acquisition is led by a consortium including Select Medical's Executive Chairman, Robert A. Ortenzio, and Senior Executive Vice President Martin F. Jackson, indicating a significant management rollover and continued involvement.
- The consortium's financial advisors and legal counsel are listed, along with the company's and special committee's advisors, detailing the professional services involved in the transaction.
Stakeholder Impact
- Shareholders will receive $16.50 per share in cash, representing a premium over recent trading prices.
- Employees will continue to be led by current officers, including Mr. Ortenzio and Mr. Jackson, suggesting potential stability in leadership.
- The company's delisting from the NYSE will change its reporting obligations and public investor access.
Next Steps
- Select Medical will now operate as a private company.
- The company's common stock will cease trading on the NYSE effective July 1, 2026.
- The consortium will maintain operational control and implement its strategic plans for the company.
Key Dates
| Date | Description |
|---|---|
| 2025-11-24 | Last trading day prior to a publicly disclosed proposal being submitted by Mr. Ortenzio to the Company's Board of Directors. |
| 2026-03-02 | Date of the Agreement and Plan of Merger. |
| 2026-06-26 | Date of Select Medical's Special Meeting of Stockholders where the transaction was approved. |
| 2026-06-30 | Date of announcement of the completion of the acquisition and the date of Amendment No. 12 to the Credit Agreement. |
| 2026-07-01 | Effective date of the merger and the date Select Medical's common stock will cease trading on the NYSE. |
Recommendation
holdThe acquisition at a premium is positive for existing shareholders, but the delisting and increased debt from the new term loan introduce uncertainties for future investment. A 'hold' recommendation reflects a neutral stance pending further clarity on the company's private operational strategy and financial performance under new ownership.
Keywords
Select Medical Holdings, Acquisition, Merger, Private Equity, Welsh Carson Anderson & Stowe, Robert A. Ortenzio, Martin F. Jackson, NYSE Delisting, Credit Agreement Amendment, Term Loan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.